Adma Biologics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
22.3%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$535.3Mnext fiscal year
FY EPS (est.)
$0.80next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 4 Nov 2026 |
Monitoring Framework
Key Performance Indicators
ASCENIV Product Revenue Quarterly97.5MTarget: Continued double-digit growth driven by pediatric label expansion and direct-to-patient initiatives
BIVIGAM Product Revenue Quarterly15.4MTarget: Stabilization of sales volume amid standard IG pricing pressure and competitive PDT inventories
Gross Margin Quarterly71.0%Target: Sustained expansion driven by yield-enhanced production and high-margin IVIG product mix
Cash Flow from Operations Quarterly58.2MTarget: Positive cash generation to support capital-efficient supply model and share repurchases
Watch Items
- Securities Class Action LitigationTrigger: Lead plaintiff appointment deadline of August 10, 2026, or any court rulings on motions to dismissAction: Monitor legal developments, disclosure requirements, and potential impact on corporate reputation or financial reserves
- Accounts Receivable and Days Sales Outstanding (DSO)Trigger: Receivables exceeding $135.9 million or collection cycles extending beyond historical averagesAction: Evaluate cash collection efficiency to address short-seller allegations of channel stuffing and delayed cash conversion
- Standard Immunoglobulin (IG) Market PricingTrigger: Aggressive discounting, rebating, or elevated raw material plasma supply in the broader PDT marketAction: Assess competitive dynamics impacting BIVIGAM sales and determine if further product mix shifts toward ASCENIV are required
Research as of 19 Jun 2026